Disc challenges in polycythemia vera, but Silence retains the lead on September 11, 2026 Disc Medicine DISC-3405 divesiran hepcidin Phase 2 trial Phase 3 development Polycythemia SANRECO Silence Therapeutics TMPRSS6 gene vera +
Disc Medicine reports promising early PV data on September 11, 2026 Disc Medicine DISC-3405 Frazier Life Sciences investing Phase 2 Polycythemia public fund RESTORE-PV Venous blood sampling vera +
FDA approves first-in-class Mimrylo for rare blood cancer on August 31, 2026 Approved Hematologic Neoplasms hepcidin Infrequent mimetics Mimrylo Polycythemia rusfertide Takeda United States Food and Drug Administration vera VERIFY trial +
Zealand's royalty deal on August 14, 2026 Clinical Trials IGF-1R inhibitor Khartis Therapeutics NALF2 gene Oral Medicine Pharma Polycythemia royalty rusfertide PTG-300 Takeda Protagonist Therapeutics Thyroid associated opthalmopathies Vera Zealand +
Zealand Sells Rights to Takeda’s Blood Cancer Drug for $100M Ahead of FDA Approval Decision on August 13, 2026 Approved goal Hematologic Neoplasms Hepcidin Mimetic PTG-300 PDUFA Pharma Polycythemia royalty rusfertide Takeda United States Food and Drug Administration Vera Zealand Pharma +
Phase II win for Silence's divesiran in PV lifts bar for Takeda's rusfertide on August 12, 2026 88% Clinical Response divesiran dosing Frequency of Responses Hepcidin mimetics NDA Perl50 Phase II SANRECO Polycythemia Priority Review siRNA therapy Takeda rusfertide Trimonthly Venous blood sampling vera PV +
Gene‑silencing drug divesiran posts strong Phase 2 win in rare blood cancer on August 11, 2026 divesiran gene-silencing Hematocrit procedure Hematologic Neoplasms Hepcidin Infrequent Polycythemia RNA, Small Interfering rusfertide SANRECO Silence Therapeutics ' Takeda TMPRSS6 gene Venous blood sampling Vera +
Ono Pharmaceutical Acquires Global Rights to Ionis' Sapablursen for Polycythemia Vera in $940M Deal on March 12, 2025 Dosage Forms licensing agreement Polycythemia RNA-targeted medicine Sapablursen vera +